Hospital Universitario Arnau de Vilanova -ko ikertzaileekin lankidetzan egindako argitalpenak (13)

2024

  1. Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Vol. 65, Núm. 5, pp. 708-713

2021

  1. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

    Breast Cancer Research, Vol. 23, Núm. 1

  2. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

    npj Precision Oncology, Vol. 5, Núm. 1

  3. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients

    Cancer Treatment Reviews, Vol. 83

  2. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

    Journal of the National Cancer Institute, Vol. 112, Núm. 1, pp. 46-54

  3. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

    Breast Cancer Research, Vol. 22, Núm. 1

  4. Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

    Clinical Cancer Research, Vol. 26, Núm. 22, pp. 5820-5829

  5. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

    Nature Communications, Vol. 11, Núm. 1

  6. Randomized phase 0/I trial of the mitochondrial inhibitor Me-344 or placebo added to bevacizumab in early HER2-negative breast cancer

    Clinical Cancer Research, Vol. 26, Núm. 1, pp. 35-45

2018

  1. A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: Final results of the IBCSG 42-12/BIG 2-12 SNAP trial

    Annals of Oncology, Vol. 29, Núm. 3, pp. 661-668

2017

  1. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

  2. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

    The Lancet Oncology, Vol. 18, Núm. 4, pp. 545-554